Lynwood discloses 5% stake in Rein Therapeutics
Lynwood Capital Management Inc., Ben Shapiro and Lynwood Opportunities Master Fund reported beneficial ownership of 4,280,500 shares of Rein Therapeutics, Inc. common stock, representing 5.0% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Lynwood Capital Management Inc., Ben Shapiro and Lynwood Opportunities Master Fund reported beneficial ownership of 4,280,500 shares of Rein Therapeutics, Inc. common stock, representing 5.0% of the class. The shares are directly held by the Fund, with the Investment Manager and Mr. Shapiro deemed beneficial owners through control of the Fund.
The ownership percentages are based on 85,539,032 shares of common stock outstanding as of May 21, 2026. Each reporting person has sole voting and dispositive power over the 4,280,500 shares and disclaims beneficial ownership of any other shares.
Key Figures
Key Terms
beneficial ownership financial
sole voting power financial
sole dispositive power financial
Schedule 13G regulatory
CUSIP No. financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Rein Therapeutics (RNTX) does Lynwood report owning?
Who are the reporting persons in this Schedule 13G/A for Rein Therapeutics (RNTX)?
What voting and dispositive powers do the Lynwood entities report over Rein Therapeutics (RNTX) shares?
Where are the Lynwood Opportunities Master Fund and Investment Manager for Rein Therapeutics (RNTX) organized?
AI-generated analysis. How Rhea-AI works. Not financial advice.